PMID- 29334322
OWN - NLM
STAT- MEDLINE
DCOM- 20200804
LR  - 20200804
IS  - 1814-1412 (Electronic)
IS  - 1562-2975 (Linking)
VI  - 20
IP  - 7
DP  - 2019 Sep
TI  - Plasma brain-derived neurotrophic factor (pBDNF) and executive dysfunctions in 
      patients with major depressive disorder.
PG  - 519-530
LID - 10.1080/15622975.2018.1425478 [doi]
AB  - Objectives: Executive dysfunctions are frequently seen in patients with major 
      depressive disorder (MDD) and normalise in many cases during effective 
      antidepressant therapy. This study investigated whether a normalisation of 
      executive dysfunctions during antidepressant treatment correlates with or can be 
      predicted by clinical parameters or levels of brain-derived neurotrophic factor 
      (BDNF).Methods: In 110 MDD patients with executive dysfunctions (percentile <16), 
      executive functions and plasma BDNF levels were analysed at baseline, and days 14 
      and 56 of an antidepressant treatment. BDNF exon IV and P11 methylation status 
      was studied at baseline.Results: Eighty patients (73%) experienced a 
      normalisation of executive dysfunctions, while 30 (27%) suffered from persistent 
      dysfunctions until day 56. Patients with persistent dysfunctions had 
      significantly higher HAMD scores at days 14 and 56, and lower plasma BDNF levels 
      at each time point than patients with a normalisation of dysfunctions 
      (F(1)= 10.18; P = 0.002). This was seen for verbal fluency, but not processing 
      speed. BDNF exon IV and p11 promoter methylation was not associated with test 
      performance.Conclusions: Our results corroborate a concomitant amelioration of 
      executive dysfunctions with successful antidepressant therapy and support a role 
      of BDNF in the neural mechanisms underlying the normalisation of executive 
      dysfunctions in MDD.ClinicalTrials.gov number: NCT00974155; EudraCT: 
      2008-008280-96.
FAU - Wagner, Stefanie
AU  - Wagner S
AD  - Department of Psychiatry and Psychotherapy, University Medical Centre, Mainz, 
      Germany.
FAU - Kayser, Sarah
AU  - Kayser S
AD  - Department of Psychiatry and Psychotherapy, University Medical Centre, Mainz, 
      Germany.
FAU - Engelmann, Jan
AU  - Engelmann J
AD  - Department of Psychiatry and Psychotherapy, University Medical Centre, Mainz, 
      Germany.
FAU - Schlicht, Konrad F
AU  - Schlicht KF
AD  - Department of Psychiatry and Psychotherapy, University Medical Centre, Mainz, 
      Germany.
FAU - Dreimuller, Nadine
AU  - Dreimuller N
AD  - Department of Psychiatry and Psychotherapy, University Medical Centre, Mainz, 
      Germany.
FAU - Tuscher, Oliver
AU  - Tuscher O
AD  - Department of Psychiatry and Psychotherapy, University Medical Centre, Mainz, 
      Germany.
FAU - Muller-Dahlhaus, Florian
AU  - Muller-Dahlhaus F
AD  - Department of Psychiatry and Psychotherapy, University Medical Centre, Mainz, 
      Germany.
FAU - Braus, Dieter F
AU  - Braus DF
AD  - Department of Psychiatry and Psychotherapy, HELIOS Dr. Horst-Schmidt-Kliniken, 
      Wiesbaden, Germany.
FAU - Tadic, Andre
AU  - Tadic A
AD  - Department of Psychiatry and Psychotherapy, University Medical Centre, Mainz, 
      Germany.
AD  - Department of Psychiatry, Psychosomatics and Psychotherapy, Agaplesion 
      Elisabethenstift, Darmstadt, Germany.
FAU - Neyazi, Alexandra
AU  - Neyazi A
AD  - Molecular Neuroscience Laboratory, Department of Psychiatry, Social psychiatry 
      and Psychotherapy, Hannover Medical School (MHH), Hannover, Germany.
FAU - Frieling, Helge
AU  - Frieling H
AD  - Molecular Neuroscience Laboratory, Department of Psychiatry, Social psychiatry 
      and Psychotherapy, Hannover Medical School (MHH), Hannover, Germany.
FAU - Lieb, Klaus
AU  - Lieb K
AD  - Department of Psychiatry and Psychotherapy, University Medical Centre, Mainz, 
      Germany.
LA  - eng
SI  - ClinicalTrials.gov/NCT00974155
SI  - EudraCT/2008-008280-96
PT  - Clinical Trial, Phase IV
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20180202
PL  - England
TA  - World J Biol Psychiatry
JT  - The world journal of biological psychiatry : the official journal of the World 
      Federation of Societies of Biological Psychiatry
JID - 101120023
RN  - 0 (Antidepressive Agents)
RN  - 0 (Brain-Derived Neurotrophic Factor)
SB  - IM
MH  - Adult
MH  - Antidepressive Agents/blood/*therapeutic use
MH  - Brain-Derived Neurotrophic Factor/*blood/*genetics
MH  - Depressive Disorder, Major/*blood/*drug therapy
MH  - *Executive Function
MH  - Female
MH  - Germany
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Predictive Value of Tests
MH  - Promoter Regions, Genetic
MH  - Psychiatric Status Rating Scales
MH  - Time Factors
OTO - NOTNLM
OT  - BDNF exon IV and p11 promoter methylation
OT  - Major depressive disorder
OT  - antidepressant therapy
OT  - brain-derived neurotrophic factor
OT  - executive function
EDAT- 2018/01/16 06:00
MHDA- 2020/08/05 06:00
CRDT- 2018/01/16 06:00
PHST- 2018/01/16 06:00 [pubmed]
PHST- 2020/08/05 06:00 [medline]
PHST- 2018/01/16 06:00 [entrez]
AID - 10.1080/15622975.2018.1425478 [doi]
PST - ppublish
SO  - World J Biol Psychiatry. 2019 Sep;20(7):519-530. doi: 
      10.1080/15622975.2018.1425478. Epub 2018 Feb 2.